+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oral Proteins and Peptides Market by Drug Type and by Application: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2024

  • ID: 4854347
  • Report
  • September 2018
  • Region: Global
  • 110 pages
  • Zion Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

The report covers forecast and analysis for the oral proteins and peptides market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the oral proteins and peptides market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the oral proteins and peptides market on a global level.

In order to give the users of this report a comprehensive view of the oral proteins and peptides market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a customer and region segments which are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the market on the global and regional basis. 

The study provides a decisive view of the oral proteins and peptides market by segmenting the market based on customer and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2025.

By drug type, the global oral proteins and peptides market is divided into insulin, linaclotide, calcitonin, plecanatide, and octreotide. Among these products, insulin is expected to account for the largest share of the market. Linaclotide was the fastest growing segment in 2017 and is expected to grab the largest share of total revenue in the coming years.

By application segment, the global oral proteins and peptides market is divided into diabetes, bone diseases, hormonal disorders, gastric & digestive disorders, and others. Diabetes was the leading application segment accounting largest revenue share in 2016. 

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further divided into major countries including the U.S., Germany, France, the UK, China, Japan, India, and Brazil. This segmentation includes demand for oral proteins and peptides based on individual segment and applications in all the regions and countries.

Some of the key players in oral proteins and peptides market include Allergan Plc, Chiasma, Inc., Synthetic Biologics, Generex Biotechnology Corp., Proxima Concepts Limited (Diabetology Ltd.), Novo Nordisk A/S, and Tarsa Therapeutics Inc., Synergy Pharmaceuticals Inc., Sanofi S.A., Biocon Limited, F. Hoffmann-La Roche AG, AstraZeneca Plc, Inc., Hovione Limited, Novartis International AG, among others.

This report segments the global oral proteins and peptides market as follows:

Global Oral Proteins and Peptides Market: Drug Type Segment Analysis

  • Integrated Drug
  • Linaclotide
  • Plecanatide
  • Calcitonin
  • Insulin 
  • Octreotide 

Global Oral Proteins and Peptides Market: Application Segment Analysis

  • Gastric & Digestive Disorders
  • Bone Diseases
  • Diabetes 
  • Hormonal Disorders
  • Others

Global Oral Proteins and Peptides Market: Regional Segment Analysis

  • North America
  • The U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • The Middle East and Africa
Note: Product cover images may vary from those shown
2 of 2
  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global Oral Proteins and Peptides Market, 2015 - 2025 (USD Billion)
    • 2.2. Global Oral Proteins and Peptides Market: Snapshot
  • Chapter 3. Oral Proteins and Peptides - Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Oral Proteins and Peptides Market drivers: Impact analysis
      • 3.2.2. Growing prevalence of chronic diseases
      • 3.2.3. The increasing emphasis of key players on research and development activities
    • 3.3. Market Restraints
      • 3.3.1. Lack of awareness among consumers
      • 3.3.2. Stringent regulation policies
      • 3.3.3. Contradictions on efficacy and efficiency of oral peptides are expected to hamper growth of market
    • 3.4. Opportunities
      • 3.4.1. Rising number of oral protein formulations is projected to offer lucrative opportunities in forecast period
      • 3.4.2. Untapped Markets
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Drug Type
      • 3.6.2. Market attractiveness analysis, by Application Type
      • 3.6.3. Market attractiveness analysis, by Regional segment
  • Chapter 4. Global Oral Proteins and Peptides Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Oral Proteins and Peptides market: company market share, 2017
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Regional Expansion
  • Chapter 5. Global Oral Proteins and Peptides Market - Drug Type Segment Analysis
    • 5.1. Global Oral Proteins and Peptides market: Drug Type overview
      • 5.1.1. Global Oral Proteins and Peptides market revenue share, by Drug Type, 2015 and 2025
      • 5.1.2. Global Oral Proteins and Peptides market revenue share, by Linaclotide, 2015 - 2025
      • 5.1.3. Global Oral Proteins and Peptides market revenue share, by Plecanatide, 2015 - 2025
      • 5.1.4. Global Oral Proteins and Peptides market revenue share, by Calcitonin, 2015 - 2025
      • 5.1.5. Global Oral Proteins and Peptides market revenue share, by Insulin, 2015 - 2025
      • 5.1.6. Global Oral Proteins and Peptides market revenue share, by Octreotide, 2015 - 2025
  • Chapter 6. Global Oral Proteins and Peptides Market - Application Segment Analysis
    • 6.1. Global Oral Proteins and Peptides Market: Application overview
      • 6.1.1. Global Oral Proteins and Peptides market revenue share, Application, 2015 and 2025
      • 6.1.2. Global Oral Proteins and Peptides market for Gastric & Digestive Disorders, 2015 - 2025(USD Billion)
      • 6.1.3. Global Oral Proteins and Peptides market for Bone Diseases, 2015 - 2025(USD Billion)
      • 6.1.4. Global Oral Proteins and Peptides market for Diabetes, 2015 - 2025(USD Billion)
      • 6.1.5. Global Oral Proteins and Peptides market for Hormonal Disorders, 2015 - 2025(USD Billion)
      • 6.1.6. Global Oral Proteins and Peptides market for Others, 2015 - 2025(USD Billion)
  • Chapter 7. Global Oral Proteins and Peptides Market - Regional Segment Analysis
    • 7.1. Global Oral Proteins and Peptides market: Regional overview
      • 7.1.1. Global Oral Proteins and Peptides market revenue share, by region, 2015 and 2025
    • 7.2. North America
      • 7.2.1. North America Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
      • 7.2.2. North America Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.2.3. U.S.
        • 7.2.3.1. U.S. Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.2.3.2. U.S. Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
    • 7.3. Europe
      • 7.3.1. Europe Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
      • 7.3.2. Europe Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.3.3. U.K.
        • 7.3.3.1. U.K. Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.3.3.2. U.K. Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.3.4. Germany
        • 7.3.4.1. Germany Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.3.4.2. Germany Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.3.5. France
        • 7.3.5.1. France Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.3.5.2. France Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
      • 7.4.2. Asia Pacific Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.4.3. China
        • 7.4.3.1. China Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.4.3.2. China Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.4.4. Japan
        • 7.4.4.1. Japan Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.4.4.2. Japan Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.4.5. India
        • 7.4.5.1. India Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.4.5.2. India Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
    • 7.5. Latin America
      • 7.5.1. Latin America Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
      • 7.5.2. Latin America Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
        • 7.5.3.2. Brazil Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
    • 7.6. Middle East and Africa
      • 7.6.1. Middle East and Africa Oral Proteins and Peptides market revenue, by Drug Type, 2015 - 2025(USD Billion)
      • 7.6.2. Middle East and Africa Oral Proteins and Peptides market revenue, by Application, 2015 - 2025(USD Billion)
  • Chapter 8. Company Profile
    • 8.1. Allergan plc
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Therapy portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Sanofi S.A.
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Therapy portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. F. Hoffmann-La Roche AG
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Therapy portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. AstraZeneca Plc.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Therapy portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. Proxima Concepts Limited
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Therapy portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Tarsa Therapeutics Inc
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Therapy portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Merge Healthcare Inc
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Therapy portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. Chiasma, Inc.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Therapy portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments
    • 8.9. Synthetic Biologics
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Therapy portfolio
      • 8.9.4. Business strategy
      • 8.9.5. Recent developments
    • 8.10. Generex Biotechnology Corp.
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Therapy portfolio
      • 8.10.4. Business strategy
      • 8.10.5. Recent developments
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll